We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Mar 2022 - 09 Mar 2022
Virtual Venue

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

By LabMedica International staff writers
Posted on 30 Nov 2021
Print article
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)
Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous group of breast cancers that exhibit distinct morphologic features and biological behavior.

Forkhead box transcription factor C1 (FOXC1) is a member of the forkhead box (FOX) transcription factor family, which plays an essential role in embryonic development and maintenance of adult stem and progenitor cell compartments. In breast cancer, high FOXC1 expression enhances the proliferation, migratory ability, and epithelial-mesenchymal transition of basal-like breast cancer (BLBC) cells.

Pathologists at the Shanghai Medical College (Shanghai, China) enrolled in a study a cohort of 2,443 patients diagnosed with invasive breast cancer without distant metastasis between July 2019 and April 2020. Pathologic staging including tumor size (T) and lymph node (N) status was determined by surgical resection. Tumor histologic grading was performed according to the Nottingham grading system by assessing the following three morphologic features: tubule formation, nuclear pleomorphism, and mitotic counts. Hematoxylin-eosin–stained slides were reviewed.

All staining was performed with a Ventana BenchMark Ultra autostainer (Ventana Medical System Inc, Roche, Tucson, AZ. USA). Only nuclear staining was considered for positive AR, FOXC1, and GATA3 expression, whereas cytoplasmic staining characterized positive cytokeratin (CK) 5/6, CK14, and GCDFP-15 expression. Androgen receptor was assessed semiquantitatively with the Allred scoring method, which incorporates the intensity and distribution of reactivity. Immunohistochemistry staining with AR, GCDFP15, CK5/6, and CK14 was considered positive when more than 1% tumor cells were stained. FOXC1 was assessed semiquantitatively according to the distribution of reactivity.

The investigators reported that the expression rate of FOXC1 in TNBC was significantly higher than in other subtypes. The area under the ROC curve confirmed the high diagnostic value of FOXC1 for the prediction of the triple-negative phenotype. The cutoff value of 1% showed a maximized sum of sensitivity and specificity. In TNBC, FOXC1 expression was significantly associated with aggressive tumor phenotypes. Furthermore, FOXC1 expression was primarily observed in invasive breast carcinoma of no special type and metaplastic carcinoma, but rarely in invasive carcinoma with apocrine differentiation. Correspondingly, FOXC1 expression was significantly associated with the expression of basal markers but was negatively correlated with apocrine-related markers in TNBC.

The authors concluded that FOXC1 is a highly specific marker for the triple-negative phenotype. Moreover, immunohistochemical detection of FOXC1 expression can be used as an additional diagnostic tool for the triple-negative phenotype and subclassification in TNBC. The study was published on November 16, 2021 in the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Shanghai Medical College
Ventana Medical System

Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
Live Cell Analysis System
BioTek BioSpa
Atomic Fluorescence Spectrometer
Portable Tube Luminometer
Junior LB 9509

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more


view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.